Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01239875 · ClinicalTrials.gov registry record · Early Phase 1

Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma

A Early Phase 1 study, sponsored by Mayo Clinic.

Completed
Registry status
Early Phase 1
Development phase
16
Enrollment target

NCT01239875: Completed Early Phase 1 study, sponsored by Mayo Clinic.

NCT01239875 is a Early Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 16 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (70% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT01239875, a Early Phase 1 study, has completed, sponsored by Mayo Clinic.

COMPLETED
Registry status
Early Phase 1
Development phase
16 participants
Enrollment target

Study Summary

RATIONALE: Vaccines, such as dendritic cell therapy (DC) made from a person's tumor cells and white blood cells may help the body build an effective immune response to kill tumor cells. Cryosurgery kills cancer cells by freezing them. Giving vaccine therapy together with cryosurgery may kill more tumor cells. PURPOSE: This clinical trial studies giving vaccine therapy together with or without cryosurgery in treating patients with B-cell Non-Hodgkin's lymphoma.

Interventions

  • OTHER laboratory biomarker analysis
  • OTHER immunoenzyme technique
  • BIOLOGICAL pneumococcal polyvalent vaccine
  • PROCEDURE cryotherapy
  • BIOLOGICAL dendritic cell vaccine therapy

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2010-11
Est. Completion 2019-07-17
Phase Early Phase 1
Mayo Clinic

2,844 total trials

What the finished NCT01239875 record still lists

NCT01239875 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (70% lower).

The record links to 0 conditions, and to 5 interventions - of which laboratory biomarker analysis is the first listed.

NCT01239875 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01239875 about?

NCT01239875 is a clinical study titled "Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma". RATIONALE: Vaccines, such as dendritic cell therapy (DC) made from a person's tumor cells and white blood cells may help the body build an effective immune response to kill tumor cells. Cryosurgery kills cancer cells by freezing them. Giving vaccine therapy together with cryosurgery may kill more tu...

What is the current status of trial NCT01239875?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 16 participants. The study started on 2010-11. Estimated completion is 2019-07-17.

What interventions are being tested in trial NCT01239875?

The interventions under investigation include: laboratory biomarker analysis (OTHER), immunoenzyme technique (OTHER), pneumococcal polyvalent vaccine (BIOLOGICAL), cryotherapy (PROCEDURE), dendritic cell vaccine therapy (BIOLOGICAL).

Who is sponsoring clinical trial NCT01239875?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01239875's enrollment target sits among peer trials

16 1369th of 2000 higher than 598 of 2,000 other Early Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02422641 · 16 participants · Phase 2

    Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis

  • NCT02851758 · 16 participants · NA

    Transplantation of Autologously Derived Mitochondria Following Ischemia

  • NCT03291028 · 16 participants

    Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma

  • NCT03425526 · 16 participants · Phase 1

    Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01239875, the US trial registry maintained by the National Library of Medicine. NCT01239875 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.